Texas Senate Bill SB 29

Texas 2025 - 89th 2nd C.S.

• Filed: 8/15/25

Caption

Relating to a statewide order issued by the commissioner of state health services authorizing a pharmacist to dispense ivermectin.

Summary

SB 29 would require the Texas commissioner of state health services to issue a statewide order allowing licensed pharmacists to dispense ivermectin without a prescription from a health care practitioner. The order must include standardized written protocols for pharmacists and require them to give patients instructions on proper use. The bill also directs pharmacists to follow the statewide order when dispensing the drug and allows the executive commissioner and Texas State Board of Pharmacy to adopt rules to carry out the law. The bill further provides liability protections for pharmacists who act in a reasonably prudent manner while dispensing ivermectin under the statewide order, shielding them from criminal, civil, and professional disciplinary consequences. Pharmacists would also have to submit annual reports on the number of ivermectin doses dispensed under the order, creating a reporting mechanism for state oversight. The commissioner’s issuance of the order is likewise protected from liability or disciplinary action. In practical terms, SB 29 would change state health and pharmacy law by creating a specific statutory exception to the general prescription requirement for ivermectin. It would authorize dispensing statewide without a prescription, superseding conflicting laws and giving the health commissioner direct authority to establish the order and related protocols. The bill would affect pharmacists, the Texas Department of State Health Services, and the Texas State Board of Pharmacy, while also creating a new reporting obligation for participating pharmacists. Because there are no committee transcripts or recorded votes in the provided materials, there is no documented debate or formal vote history to gauge sentiment. Based on the bill text alone, the measure appears designed to expand access and reduce legal risk for pharmacists, suggesting support from proponents of broader ivermectin access. At the same time, the absence of discussion records means any opposition or concerns are not captured in the available context. The main point of contention likely concerns whether ivermectin should be available without a prescription and whether the state should direct pharmacists to dispense it statewide. Potential concerns include patient safety, appropriate medical oversight, professional standards, and the policy implications of granting broad immunity and authority to dispense a medication outside the usual prescription process.

Impact

SB 29 would amend the Texas Health and Safety Code to add a new section requiring a statewide order for pharmacist dispensing of ivermectin without a prescription. It would override conflicting law, authorize pharmacists to dispense under standardized protocols, require patient instructions and annual reporting, and provide liability and disciplinary protections for pharmacists and the commissioner. The bill would directly affect pharmacy practice, state public health administration, and oversight by the Texas State Board of Pharmacy.

Sentiment

The available record shows no committee transcripts and no votes, so there is no documented legislative sentiment beyond the bill text itself. The measure appears to be framed as an access-and-liability-protection bill for pharmacists, which suggests likely support from sponsors and advocates for expanded ivermectin availability. However, without recorded debate, the extent of support or opposition cannot be determined from the provided materials.

Contention

The likely controversy is whether the commissioner should be required to authorize nonprescription dispensing of ivermectin statewide and whether pharmacists should be protected from liability when doing so. Opponents would likely focus on medical appropriateness, safety, and the role of prescription oversight, while supporters would emphasize access, pharmacist discretion, and legal protection. The bill also raises questions about state authority to mandate dispensing protocols and reporting requirements for a drug that is ordinarily dispensed by prescription.